{"id":"NCT01777191","sponsor":"Eli Lilly and Company","briefTitle":"Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis","officialTitle":"Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2014-05","completion":"2015-05","firstPosted":"2013-01-28","resultsPosted":"2016-05-26","lastUpdate":"2019-09-30"},"enrollment":204,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Ixekizumab Auto-Injector","otherNames":["LY2439821"]},{"type":"DRUG","name":"Ixekizumab Prefilled Syringe","otherNames":["LY2439821"]}],"arms":[{"label":"80 mg Ixekizumab Auto-Injector","type":"EXPERIMENTAL"},{"label":"80 mg Ixekizumab Prefilled Syringe","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.","primaryOutcome":{"measure":"Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device","timeFrame":"Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)","effectByArm":[{"arm":"80 mg Ixekizumab Prefilled Syringe","deltaMin":15,"sd":null},{"arm":"80 mg Ixekizumab Auto-Injector","deltaMin":14.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":25,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["27500949"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":102},"commonTop":["Upper respiratory tract infection","Injection site reaction"]}}